Novartis (NVS) has obtained a temporary order from the US Court of Appeals for the Federal Circuit, preventing MSN Pharmaceuticals from launching a generic version of its heart-failure drug, Entresto, according to the court order on Thursday.
MSN Pharmaceuticals had planned to launch its generic on Thursday, coinciding with the expiration of Novartis' patent, Reuters reported late Thursday.
The court said it decision would allow time to consider Novartis' request for a longer ban on the generic release.
The decision comes after the Federal Circuit last week overturned a 2023 ruling that invalidated one of Novartis' patents, which the company argued protects its exclusive rights to Entresto until July.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。